Gw Pharmaceuticals (GWPRF)

GW Pharmaceuticals PLC was incorporated on February 15, 2001 under the laws of England and Wales. It is engaged in the research, development and commercialization of cannabinoid prescription medicines to meet patient needs. Its reportable segments are Sativex Commercial, Sativex Research and Development, and Pipeline Research and Development. The Sativex Commercial segment promotes Sativex through strategic collaborations with major pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The current focus for this segment is the Phase III clinical development programme of Sativex for use in treatment of cancer pain. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using the Group's proprietary cannabinoid technology platform and partnerships with international scientists. The company has operations in the United Kingdom, Europe, United States, Canada and Asia. Trademark Epidiolex is registered in the United Kingdom and approved for publication in the United States. The Company is subject to regulation by federal, state and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services, the U.S. Department of Justice and individual U.S. Attorney offices within the Department of Justice, and state and local governments.